Effect of losartan combined with spironolactone in the treatment of coronary artery microembolization

Objevtive To analyze the efficacy of losartan combined with spironolactone in the treatment of coronary artery microembolization and its effects on levels of serum matrix metalloproteinase-9(MMP-9), tissue inhibitor of metalloproteinase-1(TIMP-1), high sensitivity C reactive protein(hs-CRP). Methods Sixty-four patients with coronary artery microembolism admitted to our hospital were randomly divided into two groups. The control group(n=32)was treated with losartan, and the experimental group(n=32)was treated with lozafloxacin and spironolactone. The clinical efficacy, cardiac function indicators, serum MMP-9, TIMP-1, hs-CRP levels were compared. Results The total clinical effective rate in the experimental group was significantly higher than that in the control group(93.75% vs. 65.62%, P<0.05). After treatment, the experimental group had significantly lower results in left ventricular end-diastolic diameter(LVEDD), left ventricular end systolic diameter(LVESD), MMP-9, TIMP-1, hs-CRP levels than the control group, and left ventricular ejection fraction(LVEF)was significantly higher than that in the control group(P<0.05). Conclusion Losartan combined with spironolactone can effectively improve the clinical symptoms of patients with coronary artery microembolism, inhibit level of inflammatory factors such as hs-CRP, and improve the heart function.